These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 16628132)

  • 1. Population pharmacokinetics of oxaliplatin (85 mg/m2) in combination with 5-fluorouracil in patients with advanced colorectal cancer.
    Kho Y; Jansman FG; Prins NH; Neef C; Brouwers JR
    Ther Drug Monit; 2006 Apr; 28(2):206-11. PubMed ID: 16628132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Administration of reduced glutathione in FOLFOX4 adjuvant treatment for colorectal cancer: effect on oxaliplatin pharmacokinetics, Pt-DNA adduct formation, and neurotoxicity.
    Milla P; Airoldi M; Weber G; Drescher A; Jaehde U; Cattel L
    Anticancer Drugs; 2009 Jun; 20(5):396-402. PubMed ID: 19287306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and pharmacokinetics study of oxaliplatin in colon cancer patients.
    Burz C; Berindan-Neagoe IB; Balacescu O; Tanaselia C; Ursu M; Gog A; Vlase L; Chintoanu M; Balacescu L; Leucuta SE; Irimie A; Cristea V
    J Gastrointestin Liver Dis; 2009 Mar; 18(1):39-43. PubMed ID: 19337632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetics of oxaliplatin.
    Delord JP; Umlil A; Guimbaud R; Grégoire N; Lafont T; Canal P; Bugat R; Chatelut E
    Cancer Chemother Pharmacol; 2003 Feb; 51(2):127-31. PubMed ID: 12647013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I/II study of oxaliplatin with weekly bolus fluorouracil and high-dose leucovorin (ROX) as first-line therapy for patients with colorectal cancer.
    Yamada Y; Ohtsu A; Boku N; Miyata Y; Shimada Y; Doi T; Muro K; Muto M; Hamaguchi T; Mera K; Yano T; Tanigawara Y; Shirao K
    Jpn J Clin Oncol; 2006 Apr; 36(4):218-23. PubMed ID: 16684860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population analysis of the pharmacokinetics and the haematological toxicity of the fluorouracil-epirubicin-cyclophosphamide regimen in breast cancer patients.
    Sandström M; Lindman H; Nygren P; Johansson M; Bergh J; Karlsson MO
    Cancer Chemother Pharmacol; 2006 Aug; 58(2):143-56. PubMed ID: 16465545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan.
    Yoshino T; Boku N; Onozawa Y; Hironaka S; Fukutomi A; Yamaguchi Y; Hasuike N; Yamazaki K; Machida N; Ono H
    Jpn J Clin Oncol; 2007 Sep; 37(9):686-91. PubMed ID: 17720736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oxaliplatin biotransformation and pharmacokinetics: a pilot study to determine the possible relationship to neurotoxicity.
    Shord SS; Bernard SA; Lindley C; Blodgett A; Mehta V; Churchel MA; Poole M; Pescatore SL; Luo FR; Chaney SG
    Anticancer Res; 2002; 22(4):2301-9. PubMed ID: 12174918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oxaliplatin pharmacokinetics during a four-hour infusion.
    Kern W; Braess J; Böttger B; Kaufmann CC; Hiddemann W; Schleyer E
    Clin Cancer Res; 1999 Apr; 5(4):761-5. PubMed ID: 10213210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II trial of modified FOLFOX as first-line chemotherapy in advanced colorectal cancer.
    Xiong JP; Zhang L; Zhong LX; Qiu F; Xu J; Tao QS; Xiang XJ; Yu F; Tang XM
    Anticancer Drugs; 2007 Oct; 18(9):1103-7. PubMed ID: 17704661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lack of pharmacokinetic interaction between 5-fluorouracil and oxaliplatin.
    Joel SP; Papamichael D; Richards F; Davis T; Aslanis V; Chatelut E; Locke K; Slevin ML; Seymour MT
    Clin Pharmacol Ther; 2004 Jul; 76(1):45-54. PubMed ID: 15229463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer: the European Organisation for Research and Treatment of Cancer Chronotherapy Group.
    Giacchetti S; Bjarnason G; Garufi C; Genet D; Iacobelli S; Tampellini M; Smaaland R; Focan C; Coudert B; Humblet Y; Canon JL; Adenis A; Lo Re G; Carvalho C; Schueller J; Anciaux N; Lentz MA; Baron B; Gorlia T; Lévi F;
    J Clin Oncol; 2006 Aug; 24(22):3562-9. PubMed ID: 16877722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II study of oxaliplatin with low dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) as first line therapy for patients with advanced gastric cancer.
    Oh SY; Kwon HC; Seo BG; Kim SH; Kim JS; Kim HJ
    Acta Oncol; 2007; 46(3):336-41. PubMed ID: 17450469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatic arterial infusion of oxaliplatin and intravenous LV5FU2 in unresectable liver metastases from colorectal cancer after systemic chemotherapy failure.
    Boige V; Malka D; Elias D; Castaing M; De Baere T; Goere D; Dromain C; Pocard M; Ducreux M
    Ann Surg Oncol; 2008 Jan; 15(1):219-26. PubMed ID: 17896145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An EORTC phase I study of Bortezomib in combination with oxaliplatin, leucovorin and 5-fluorouracil in patients with advanced colorectal cancer.
    Caponigro F; Lacombe D; Twelves C; Bauer J; Govaerts AS; Marréaud S; Milano A; Anthoney A
    Eur J Cancer; 2009 Jan; 45(1):48-55. PubMed ID: 18809314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The efficacy and toxicity of FOLFOX regimen (a combination of leucovorin and fluorouracil with oxaliplatin) as first-line treatment of metastatic colorectal cancer.
    Matsushita H; Tsuboi K; Honda I; Kato N; Okochi O; Kobayashi D; Hattori M
    Gan To Kagaku Ryoho; 2009 May; 36(5):797-801. PubMed ID: 19461180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical pharmacokinetics of oxaliplatin and 5-fluorouracil administered in combination with leucovorin in Korean patients with advanced colorectal cancer.
    Cho HK; Lee ES; Lee JW; Park JK; Kang JH; Lee KS; Shim CK; Chung SJ; Kim DD; Kuh HJ
    J Cancer Res Clin Oncol; 2006 May; 132(5):320-6. PubMed ID: 16395593
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oxaliplatin combined with 5-fluorouracil and methotrexate in advanced colorectal cancer.
    Zampino MG; Lorizzo K; Rocca A; Locatelli M; Zorzino L; Manzoni S; Mazzetta C; Fazio N; Biffi R; De Braud F
    Anticancer Res; 2006; 26(3B):2425-8. PubMed ID: 16821627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and pharmacokinetics of intravenous levetiracetam infusion as add-on in status epilepticus.
    Uges JW; van Huizen MD; Engelsman J; Wilms EB; Touw DJ; Peeters E; Vecht CJ
    Epilepsia; 2009 Mar; 50(3):415-21. PubMed ID: 19054418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biweekly oxaliplatin in combination with continuous infusional 5-fluorouracil and leucovorin (modified FOLFOX-4 regimen) as first-line chemotherapy for elderly patients with advanced gastric cancer.
    Liu ZF; Guo QS; Zhang XQ; Yang XG; Guan F; Fu Z; Wang MY
    Am J Clin Oncol; 2008 Jun; 31(3):259-63. PubMed ID: 18525305
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.